Preliminary Experience of Imatinib after Nilotinib in the First Line Treatment of Chronic Myeloid Leukemia

MLA

Pungolino, Ester, et al. “Preliminary Experience of Imatinib after Nilotinib in the First Line Treatment of Chronic Myeloid Leukemia.” Blood, vol. 130, no. 1, Number 1 Supplement 1, Dec. 2017, p. 2889. EBSCOhost, https://doi.org/10.1182/blood.V130.Suppl_1.2889.2889.

APA

Pungolino, E., D’adda, M., Perego, A., Orlandi, E. M., Turrini, M., Borin, L. M., Iurlo, A., Artale, S., Latargia, M. L., Anghilieri, M., Malato, S., Trojani, A., Spina, F., Maria Cristina, C., Pioltelli, M. L., Elena, C., Bucelli, C., Spedini, P., Rossi, G., … Cairoli, R. (2017). Preliminary Experience of Imatinib after Nilotinib in the First Line Treatment of Chronic Myeloid Leukemia. Blood, 130(1, Number 1 Supplement 1), 2889. https://doi.org/10.1182/blood.V130.Suppl_1.2889.2889

Chicago

Pungolino, Ester, Mariella D’adda, Alessandra Perego, Ester Maria Orlandi, Mauro Turrini, Lorenza Maria Borin, Alessandra Iurlo, et al. 2017. “Preliminary Experience of Imatinib after Nilotinib in the First Line Treatment of Chronic Myeloid Leukemia.” Blood 130 (1, Number 1 Supplement 1): 2889. doi:10.1182/blood.V130.Suppl_1.2889.2889.